Granules India Ltd. News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Granules India Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Granules India Ltd.
Rating: 4
Author: Geojit BNP Paribas

Keep track of all breaking news and updates on Granules India Ltd. from all sources in a single place.

Granules India Ltd.

31 Oct 2025, 03:51PM

565.60

-1.51%

Company Update

Granules India Ltd-$ - 532482 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Schedule of the Earnings Conference call for Q2 and Half year of FY26.

pdf

Granules India Ltd.

30 Oct 2025, 10:46AM

565.60

-1.51%

Board Meeting

Granules India Ltd-$ - 532482 - Board Meeting Intimation for Inter-Alia, To Consider And Approve The …

BSE India

Granules India Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 ,inter alia, to consider and approve the unaudited financial results for the second quarter and half-year ended on September 30, 2025.

pdf

Granules India Ltd.

29 Oct 2025

565.60

-1.51%

Company Update

Granules India Ltd-$ - 532482 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Press Release

pdf

Granules India Ltd.

29 Oct 2025

565.60

-1.51%

Company Update

Granules India Ltd-$ - 532482 - Updates

BSE India

Updates

pdf

Granules India Ltd.

25 Sep 2025

565.60

-1.51%

SAST

Granules India Ltd-$ - 532482 - Closure of Trading Window

BSE India

Closure of Trading Window

pdf

Granules India Ltd.

18 Sep 2025

565.60

-1.51%

GRANULES INDIA

Accumulate: Granules India Ltd.

Target

Geojit BNP Paribas

We remain positive on Granules' long-term growth and profitability, supported by new product launches across geographies, a focus on backward integration, and rising market share. Entry into the CDMO segment via the Senn acquisition, along with higher-margin oncology filings, is expected to strengthen financials. Moreover, resolution of regulatory issues at the Gagilapur facility could act as a key re-rating catalyst. Hence, we maintain an Accumulate rating on the...

Number of FII/FPI investors decreased from 199 to 189 in Sep 2025 qtr

Granules India Ltd.

04 Sep 2025

565.60

-1.51%

Company Update

Granules India Ltd-$ - 532482 - Announcement under Regulation 30 (LODR)-Allotment

BSE India

Allotment of Equity Shares of the Company upon exercise of Employee Stock Options

pdf

Granules India Ltd.

22 Aug 2025

565.60

-1.51%

Can Granules India leverage its strong product pipeline to offset recent profit declines?

Economic Times

Granules India's stock shows a slight recovery despite reporting lower profits in the June quarter. Investors are positive about the company's product pipeline and business stabilisation. The company anticipates better growth in FY27. Approvals for six products in Europe are awaited. Granules focuses on CNS, ADHD, and oncology products. The Gagillapur facility remediation is progressing well with US FDA.

Granules India Ltd. has gained 24.14% in the last 6 Months

Granules India Ltd.

22 Aug 2025

565.60

-1.51%

Modest Q1FY26 growth; facility ramp-up to drive recovery

Buy: Granules India Ltd.

Deven Choksey

We have revised our FY26E/FY27E EPS estimates by -0.6%/-4.6% primarily to reflect a more gradual post-remediation ramp-up at Gagillapur, and a measured margin recovery amid persistent integration and operating costs.